Table 3.
Pre-treatment prognostic factors for survival in hepatic arterial infusion chemotherapy treatment
| Variables | Univariate |
Multivariate1 |
|
| HR (95%CI) | HR (95%CI) | P-value | |
| Age (< 60/≥ 60 yr) | 0.991 (0.514-1.912) | ||
| Gender (male/female) | 1.453 (0.687-3.076) | ||
| Maximal tumor size (< 10/≥ 10 cm) | 1.693 (0.894-3.204) | ||
| Tumor volume (< 400/≥ 400 cm3) | 2.509 (1.289-4.885) | 2.520 (1.252-5.072) | 0.01 |
| Child-Pugh score (5/> 5) | 2.099 (1.038-4.244) | 1.812 (0.878-3.738) | 0.108 |
| Stage | |||
| mUICC stage (III/IV) | 1.198 (0.502-2.863) | ||
| AJCC (III/IV) | 2.133 (1.085-4.193) | 1.803 (0.895-3.634) | 0.099 |
| Extrahepatic metastases | 1.508 (0.772-2.948) | ||
| Pre-HAIC treatment | 0.939 (0.503-1.755) | ||
| Portal vein thrombosis (Vp4 vs non-Vp4) | 1.603 (0.829-3.100) | ||
| AFP level (< 200/≥ 200 ng/mL) | 1.707 (0.845-3.448) | ||
| PIVKA-II (< 40/≥ 40 mAU/mL) | 2.860 (1.110-7.368) | 3.121 (1.177-8.274) | 0.022 |
1
Those variables with P < 0.05 in univariate analysis were included. AFP: Alpha-fetoprotein; AJCC: American Joint Committee on Cancer; HAIC: Hepatic arterial infusion chemotherapy; PIVKA: Protein induced by vitamin K absence or antagonist; mUICC: Modified Union for International Cancer Control.